Source: Annual Congress 2001 - Respiratory structure and function in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Ramsdell, J. D. Edelson, C. Compton, C. Vleisides, O. Amit, S. Kelsen, M. Strek, S. I. Rennard, S. Chodosh, N. Schachter (San Diego, Collegeville, Philadelphia, Chicago, Omaha, Boston, New York, United States Of America; Harlow, United Kingdom). Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial. Eur Respir J 2001; 16: Suppl. 31, 673

Member's Comments

No comment yet.

Related content which might interest you: Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 Roflumilast, a new orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 374s Year: 2002 A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Source: Eur Respir J 2009; 33: 1039-1044 Year: 2009 Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004 Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Effect of phosphodiesterase 4B inhibitor GSK256066 on leukocyte/endothelium interactions from chronic obstructive pulmonary disease: an in vitro study. Source: International Congress 2017 – Management of COPD Year: 2017 Effect of phosphodiesterase 5 inhibitor in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Treatment of COPD Year: 2009 Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Pharmacological characterisation of indacaterol (QAB149), a novel once-daily inhaled β2-agonist, on small airways in human and rat lung slices Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006 The proton pump inhibitor reduces the frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2009 - Treatment of COPD Year: 2009 Beyond corticosteroids: future prospects in the management of inflammation in COPD Source: Eur Respir Rev 2011; 20: 175-182 Year: 2011 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Physiological effects of roflumilast at rest and during exercise in COPD Source: Eur Respir J 2012; 39: 1104-1112 Year: 2012 Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors Source: Eur Respir Rev 2007; 16: 105-112 Year: 2007 Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Source: Eur Respir J 2002; 19: 936-943 Year: 2002 Effects of phosphodiesterase type 5 inhibitor on pulmonary hemodynamics in the patients with high altitude pulmonary hypertension (results of 12 week randomized, blind, placebo-controlled study) Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Long-term health status in patients with poorly reversible chronic obstructive pulmonary disease (COPD) treated with cilomilast Source: Eur Respir J 2004; 24: Suppl. 48, 540s Year: 2004